Questions.

What is the BPC-157 + TB-500 research blend?

It is a combination of two synthetic peptides — BPC-157, a 15-amino-acid pentadecapeptide modeled on a cytoprotective fragment of a protein found in human gastric juice ^[1], and TB-500, a synthetic 7-amino-acid fragment (Ac-LKKTETQ-OH) derived from the central actin-binding helix of thymosin beta-4 ^[22]. Research-peptide vendors and forums sometimes co-package or co-administer them under the informal nickname Wolverine, on the rationale that the two peptides act through complementary pathways: BPC-157 contributes a local angiogenic and cytoprotective signal at injury sites, while the TB-500 fragment contributes an intracellular actin-sequestration signal supporting cell migration ^[16]. No peer-reviewed controlled combination study has been published ^[6][16].

Why are BPC-157 and TB-500 combined in the Wolverine blend?

The mechanistic rationale is that the two peptides target different but complementary parts of the tissue-repair process. BPC-157 acts locally at injury sites, where it upregulates VEGFR2-PI3K-Akt-eNOS angiogenic signaling, modulates nitric oxide synthase activity, and shifts macrophages toward an anti-inflammatory M2 phenotype ^[4][19]. TB-500 / Tβ4 acts intracellularly, with its LKKTETQ helix binding monomeric G-actin in 1:1 stoichiometry and freeing the cytoskeletal machinery that drives cell migration and progenitor mobilization ^[22]. The argument is structural complementarity. The argument has not, however, been tested in a peer-reviewed controlled study of the combination at defined doses ^[6][16].

Is TB-500 the same molecule as thymosin beta-4?

No, and the distinction matters. Full-length thymosin beta-4 (Tβ4) is a 43-amino-acid peptide naturally found in mammalian cells. TB-500, as sold by research-chemical suppliers, is a synthetic 7-amino-acid N-acetylated fragment (Ac-LKKTETQ-OH) corresponding to residues 17 to 23 of Tβ4 ^[22]. The fragment retains the central actin-binding helix of the parent peptide, but it lacks the rest of the chain.

The practical consequence: the overwhelming majority of clinical efficacy data attributed to TB-500 in marketing copy was actually generated with the full-length 43-residue peptide — the RegeneRx and HLB Therapeutics ophthalmic programs (RGN-259) ^[13][14], the venous-stasis-ulcer Phase II ^[12], the Bock-Marquette cardiac papers ^[9][10], the 2021 NL005 first-in-human Phase I ^[15]. Head-to-head clinical equivalence of the 7-mer fragment with the full-length peptide has not been formally demonstrated ^[16].

How do BPC-157 and TB-500 work mechanistically?

BPC-157 acts at the injury site by promoting angiogenesis through the VEGFR2-PI3K-Akt-eNOS axis, modulating the nitric oxide system, activating ERK1/2 MAPK and the FAK-paxillin pathway in fibroblasts, upregulating the growth-hormone receptor in tendon fibroblasts via JAK2 ^[2], and shifting macrophages toward an anti-inflammatory M2 phenotype ^[4][19].

TB-500 / Tβ4 acts inside the cell. Its LKKTETQ helix binds G-actin in 1:1 stoichiometry, sequestering 40 to 50 percent of the cellular monomeric actin pool and regulating actin-filament dynamics that drive cell migration ^[22]. In the full-length-peptide context, this sequestration is the basis for integrin-linked-kinase activation in cardiomyocytes ^[9], mobilization of epicardial progenitor cells in adult mouse hearts ^[10], and oligodendrocyte progenitor differentiation after embolic stroke via p38 MAPK ^[17].

What does the research literature say about combining BPC-157 and TB-500?

The mechanism is plausible. The data are not. No peer-reviewed controlled head-to-head or combination preclinical study has been published that defines a synergy ratio, a combined dose, or a primary endpoint for BPC-157 paired with TB-500 (or with full-length Tβ4) ^[6][16]. The 2025 narrative review in Current Reviews in Musculoskeletal Medicine notes this explicitly; the 2025 HSS systematic review of BPC-157 makes the same point ^[7]. Combination claims that circulate in vendor and forum copy are extrapolations from each peptide's independently characterized mechanisms — not findings from a controlled study of the pair.

Is there any peer-reviewed clinical trial on the BPC-157 + TB-500 combination?

No. There is no peer-reviewed clinical trial of the BPC-157 + TB-500 combination as of mid-2025 ^[6][16]. ClinicalTrials.gov lists no active or completed registration for the pairing. The individual components have their own (limited) clinical record: BPC-157 has three small uncontrolled human reports, all from a single investigator group ^[6]; full-length thymosin beta-4 has Phase I through Phase III data in ophthalmic, dermal, and cardiac indications ^{[12][13][14][15]}. The combination has not been formally studied in humans.

What is the WADA status of BPC-157 and TB-500?

Both are prohibited at all times, in and out of competition. BPC-157 is listed under category S0 (Non-Approved Substances) of the WADA Prohibited List, explicitly named on the 2022 list (effective 1 January 2022) and on every annual list since. TB-500 and synthetic thymosin beta-4 derivatives are listed under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). A 2024 Canadian Centre for Ethics in Sport case produced a four-year ineligibility for an athlete who had used the BPC-157 + TB-500 combination. An athlete subject to anti-doping rules should not use either compound.

What is the FDA position on BPC-157 and TB-500?

Neither compound is approved by the FDA for any human indication. In September 2023, the FDA placed both BPC-157 and thymosin beta-4 / TB-500 on its Category 2 list of 503A bulk drug substances — the list of substances that may present significant safety risks and that may not be used in pharmacy compounding for human use ^[7]. Both compounds remain available through laboratory-supply channels for research use, but neither qualifies as a dietary supplement, food additive, or approved drug under U.S. federal regulation.

What doses of BPC-157 and TB-500 appear in the research literature?

BPC-157 has been studied most commonly at 10 μg/kg or 10 ng/kg in rodent injury models, given intraperitoneally, intragastrically, or in drinking water ^[1][3][4][8]. Higher doses (20 to 200 μg/kg intraperitoneally) appear in specific contexts such as ischemia-reperfusion and spinal cord injury ^[20][26]. Human BPC-157 reports have used 10 mg intravesicularly and up to 20 mg intravenously ^[6].

TB-500 / Tβ4 preclinical doses range from 0.5 to 12 mg/kg intraperitoneally in stroke and dermal models ^[17]. Human full-length Tβ4 Phase I used 0.05 to 25 μg/kg as a single IV dose and 0.5 to 5 μg/kg/day for 10 days ^[15]. Topical Phase II and Phase III ophthalmic programs used 0.01 to 0.1 percent solutions dosed up to six times daily ^[13][14].

None of these figures are a dosing recommendation. The dose section on the dosage page treats them as research context, not as a protocol.

What does Phase II/III data look like for thymosin beta-4 in wound healing and the eye?

The full-length Tβ4 record is the most developed clinical dataset relevant to the TB-500 fragment. In severe dry eye disease, a 56-day double-masked Phase II of 0.1% RGN-259 ophthalmic solution reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in total corneal fluorescein staining versus vehicle at day 56 ^[13]. In neurotrophic keratopathy, a randomized Phase III of 0.1% RGN-259 reported positive healing and comfort endpoints; the subsequent commercial Phase III (SEER-3) missed its primary endpoint ^[14]. In venous stasis ulcers, a 72-patient multi-center European Phase II of topical Tβ4 reported an approximately one-month acceleration of complete wound closure in completers across the active arms ^[12]. Dermal Phase II programs in pressure ulcers and epidermolysis bullosa reported acceleration of repair in completer subsets ^[16].

Why is the blend nicknamed Wolverine in the research community?

Wolverine is research-community vernacular for the rapid-healing phenotype that some forum users associate with the BPC-157 + TB-500 pairing. It is not a brand, not a trademark we have any license to use, and not a reference to any character or franchise. We treat it as a folk-category name — useful as a search term, not useful as a description of the underlying biology. The body-copy descriptor throughout this site is BPC-157 + TB-500 research blend.

Is the Wolverine peptide blend legal to purchase for research use?

This site does not sell either compound and does not refer readers to any vendor that does. We are an editorial project; the question of what is legal to purchase, where, and for what purpose is jurisdiction-dependent and outside what we can answer for any individual reader. What we can say with reference to the published regulatory record: both BPC-157 and TB-500 / thymosin beta-4 are FDA Category 2 substances, prohibiting their use in 503A pharmacy compounding for human use ^[7]; both are on the WADA Prohibited List for athletes ^[7]; neither is approved by the EMA, MHRA, TGA, or FDA for any human indication. State-level cosmetic and research-chemical regulations vary. Readers with specific questions should consult primary regulatory sources rather than relying on vendor pages or forums.